Bristol Net Receivables from 2010 to 2025

BMY Stock  USD 60.51  0.54  0.88%   
Bristol Myers Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2025. During the period from 2010 to 2025, Bristol Myers Net Receivables regression line of annual values had r-squared of  0.84 and arithmetic mean of  7,310,396,875. View All Fundamentals
 
Net Receivables  
First Reported
1987-12-31
Previous Quarter
14.9 B
Current Value
11.1 B
Quarterly Volatility
3.4 B
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Bristol Myers financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bristol Myers' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 B, Interest Expense of 2 B or Selling General Administrative of 8.8 B, as well as many indicators such as Price To Sales Ratio of 2.95, Dividend Yield of 0.0274 or PTB Ratio of 6.94. Bristol financial statements analysis is a perfect complement when working with Bristol Myers Valuation or Volatility modules.
  
Check out the analysis of Bristol Myers Correlation against competitors.

Latest Bristol Myers' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Bristol Myers Squibb over the last few years. It is Bristol Myers' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bristol Myers' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Bristol Net Receivables Regression Statistics

Arithmetic Mean7,310,396,875
Geometric Mean6,064,734,329
Coefficient Of Variation58.63
Mean Deviation3,595,196,484
Median6,300,000,000
Standard Deviation4,286,134,120
Sample Variance18370945.7T
Range13.9B
R-Value0.92
Mean Square Error3197902.8T
R-Squared0.84
Slope823,895,956
Total Sum of Squares275564185.4T

Bristol Net Receivables History

202511.3 B
202410.7 B
202315.3 B
202213.9 B
202112.5 B
20208.5 B
20197.7 B

About Bristol Myers Financial Statements

Bristol Myers investors use historical fundamental indicators, such as Bristol Myers' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables10.7 B11.3 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.